2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-100815B
    (RS)-AMPA 77521-29-0 99.82%
    (RS)-AMPA ((±)-AMPA) is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA does not interfere with binding sites for kainic acid or NMDA receptors.
    (RS)-AMPA
  • HY-132579A
    Tominersen sodium
    Tominersen sodium is a second-generation 2′-O-(2-methoxyethyl) antisense oligonucleotide that targets huntingtin protein (HTT) mRNA and potently suppresses HTT production. Tominersen improves survival and reduces brain atrophy in mice. Tominersen sodium can be used for the research of Huntington’s disease (HD).
    Tominersen sodium
  • HY-136181A
    YNT-185 1804978-81-1 98.46%
    YNT-185 is a nonpeptide, selective orexin type-2 receptor (OX2R) agonist, with EC50s of 0.028 and 2.75 μM for OX2R and OX1R, respectively. YNT-185 ameliorates narcolepsy-cataplexy symptoms in mouse models.
    YNT-185
  • HY-P991045
    Donanemab (Mouse IgG2a) 99.9%
    Donanemab (Mouse IgG2a) (mE8-IgG2a) is a mouse-derived IgG2 monoclonal antibody used in the research of Alzheimer's disease.
    Donanemab (Mouse IgG2a)
  • HY-W402682
    SXC2023 1695562-36-7 99.83%
    SXC2023 is an inhibitor for solute carrier family 7 member 11 (SLC7A11). SXC2023 exhibits antitumor efficacy, and ameliorates central nervous system disorder through downregulation of glutamate export.
    SXC2023
  • HY-Y0966S2
    Glycine-2-13C 20220-62-6 99.3%
    Glycine-2-13C is the 13C-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
    Glycine-2-13C
  • HY-17034
    Medetomidine 86347-14-0 99.99%
    Medetomidine is an orally active α2-adrenoceptor agonist (Ki: 1.08 nM). Medetomidine has sedative and analgesic effects. Medetomidine can cause peripheral vasoconstriction through the activation of α2 adrenoceptors on blood vessels.
    Medetomidine
  • HY-B1833
    Afloqualone 56287-74-2 99.94%
    Afloqualone (HQ-495) is an orally active central muscle relaxant and antivertiginous agent that can increase the sensitivity of GABA receptors in neurons of the lateral vestibular nucleus. Afloqualone (HQ-495) can be used in the research of low back pain and neck-arm-shoulder syndrome.
    Afloqualone
  • HY-I0008
    3-(Trifluoromethyl)cinnamic acid 779-89-5 ≥98.0%
    3-(Trifluoromethyl)cinnamic acid is a cinnamic acid derivative which can be extracted from Polygalae Radix. 3-(Trifluoromethyl)cinnamic acid exerts hepatoprotective, anti-gastric lesions and anti-neurodegenerative effects and can be used in chemical synthesis .
    3-(Trifluoromethyl)cinnamic acid
  • HY-N1487
    Oleanonic acid 17990-42-0 99.63%
    Oleanonic acid (3-Oxooleanolic acid) is an orally available triterpene that has anti-inflammatory and insecticidal properties. In vitro, oleanonic acid can improve oxidative stress, autophagy defects, ferroptosis, mitochondrial damage, and endoplasmic reticulum stress induced by Amyloid-β, and in vivo, it can alleviate myocardial hypertrophy in rats.
    Oleanonic acid
  • HY-117088
    LM11A-31 102562-74-3 99.77%
    LM11A-31, a non-peptide p75NTR (neurotrophin receptor p75) modulator, is an orally active and potent proNGF (nerve growth factor) antagonist. LM11A-31 is an amino acid derivative with high blood-brain barrier permeability and blocks p75-mediated cell death. LM11A-31 reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression.
    LM11A-31
  • HY-136500
    Prostaglandin H2 42935-17-1
    Prostaglandin H2 (PGH2) is an endothelium-derived contracting factor. Prostaglandin H2 can cause vasoconstriction. Prostaglandin H2 is the common precursor of all PGs and is produced by several cells that express cyclooxygen-ases. Prostaglandin H2 can activate PGD2 receptors CRTH2 and DP via interacting directly with the receptors and/or by giving rise to PGD2 after catalytic conversion by plasma proteins. Prostaglandin H2 can induce eosinophils migration and inhibit platelet aggregation. Prostaglandin H2 can accelerate the formation of dimers and higher oligomers of amyloid β1-42. Prostaglandin H2 can be used for the researches of inflammation and neurological disease, such as Alzheimer disease.
    Prostaglandin H2
  • HY-17001A
    Flupirtine 56995-20-1 99.98%
    Flupirtine(D 9998) is a selective neuronal potassium channel opener that also has NMDA receptor antagonist properties.
    Flupirtine
  • HY-124569
    NAB-14 1237541-73-9 98%
    NAB-14 is a potent, selective, orally active and non-competitive GluN2C/2D antagonists with an IC50 of 580 nM for GluN1/GluN2D. NAB-14 shows >800-fold selective for recombinant GluN2C and GluN2D over GluN2A and GluN2B. NAB-14 can cross the blood-brain-barrier.
    NAB-14
  • HY-130121
    MK-8719 1382799-40-7 99.55%
    MK-8719 is a highly potent and selective O-GlcNAcase (OGA) inhibitor (Ki=7.9 nM for hOGA) with excellent CNS penetration.
    MK-8719
  • HY-13027G
    DAPT (GMP) 208255-80-5 98%
    DAPT (GSI-IX) (GMP) is DAPT (HY-13027) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DAPT is a potent and orally active γ-secretase inhibitor.
    DAPT (GMP)
  • HY-12662
    PE859 1402727-29-0 99.01%
    PE859 is a potent inhibitor of both tau and Aβ aggregation with IC50 values of 0.66 and 1.2 μM, respectively.
    PE859
  • HY-16771
    Valbenazine 1025504-45-3 ≥98.0%
    Valbenazine (NBI-98854) is a vesicular monoamine transporter 2 (VMAT2) inhibitor with the Ki of 110-190 nM.
    Valbenazine
  • HY-16935
    Mavatrep 956274-94-5 99.67%
    Mavatrep (JNJ-39439335) is an orally active, selective and potent TRPV1 antagonist with high affinity for hTRPV1 channels (Ki=6.5 nM). Mavatrep antagonizes capsaicin-induced Ca2+ influx with an IC50 value of 4.6 nM. Mavatrep can be used in some studies of neuropathic pain.
    Mavatrep
  • HY-19733
    Lumateperone tosylate 1187020-80-9 99.78%
    Lumateperone (ITI-007) tosylate is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a dopamine D1 receptor modulator. Lumateperone tosylate has anticancer activity and can also be used in studies of psychiatric disorders such as schizophrenia.
    Lumateperone tosylate
Cat. No. Product Name / Synonyms Application Reactivity